[1] |
Choon SE, van de Kerkhof P, Gudjonsson JE, et al. International consensus definition and diagnostic criteria for generalized pustular psoriasis from the international psoriasis council[J]. JAMA Dermatol, 2024, 160(7): 758-768.
doi: 10.1001/jamadermatol.2024.0915
pmid: 38691347
|
[2] |
Feng JN, Guo JZ, Zhang Q, et al. Higher prevalence of generalized pustular psoriasis in Asia? A population-based study using claim data in China and a systematic review[J]. Dermatology, 2023, 239(2): 195-205.
|
[3] |
Choon SE, De La Cruz C, Wolf P, et al. Health-related quality of life in patients with generalized pustular psoriasis: a systematic literature review[J]. J Eur Acad Dermatol Venereol, 2024, 38(2): 265-280.
|
[4] |
Zhao A, Li M. Understanding the pathogenesis of generalized pustular psoriasis based on molecular genetics and immunopathology[J]. Int J Dermatol Venereol, 2022, 5(4): 199-206.
|
[5] |
Krueger JG, Pagotto A, Haftel S, et al. Targeted review of IL36RN mutations in patients with generalised pustular psoriasis[J]. Skin Health Dis, 2024, 4(2): e343.
|
[6] |
Yoshikawa T, Takeichi T, Nishida K, et al. MEFV variants are a predisposing factor for generalized pustular psoriasis[J]. J Am Acad Dermatol, 2024, 90(4): 852-854.
|
[7] |
Chen J, Xue X, Wang Z, et al. Genetic analysis of different subtypes of aseptic pustulosis in the Chinese population[J]. Clin Exp Dermatol, 2024, 49(10): 1217-1226.
|
[8] |
Choon SE, Foley PA, Asawanonda P, et al. Asia-Pacific consensus recommendations on the management of generalized pustular psoriasis[J]. J Dermatol, 2024, 51(12): 1579-1595.
|
[9] |
Wang Z, Xiang X, Chen Y, et al. Different clinical features of pediatric generalized pustular psoriasis in patients with or without IL36RN variants[J]. Dermatology, 2023, 239(2): 217-226.
|
[10] |
Uppala R, Tsoi LC, Harms PW, et al. "Autoinflammatory psoriasis"-genetics and biology of pustular psoriasis[J]. Cell Mol Immunol, 2021, 18(2): 307-317.
|
[11] |
Sugiura K, Fujita H, Komine M, et al. The role of interleukin-36 in health and disease states[J]. J Eur Acad Dermatol Venereol, 2024, 38(10): 1910-1925.
doi: 10.1111/jdv.19935
pmid: 38779986
|
[12] |
Lan Y, Wu X, Zhong X, et al. Increased neutrophil-derived IL-17A identified in generalized pustular psoriasis[J]. Exp Dermatol, 2024, 33(2): e15026.
|
[13] |
Kodali N, Blanchard I, Kunamneni S, et al. Current management of generalized pustular psoriasis[J]. Exp Dermatol, 2023, 32(8): 1204-1218.
|
[14] |
Lu J, Yu Q, Huang D, et al. Spesolimab rapidly treats generalized pustular psoriasis and improves the skin immune microenvironment in Chinese patients[J]. Clin Immunol, 2024, 265: 110280.
|
[15] |
Hospach T, Glowatzki F, Blankenburg F, et al. Scoping review of biological treatment of deficiency of interleukin-36 receptor antagonist (DITRA) in children and adolescents[J]. Pediatr Rheumatol Online J, 2019, 17(1): 37.
doi: 10.1186/s12969-019-0338-1
pmid: 31286990
|
[16] |
Menter A, Cordoro KM, Davis D, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients[J]. J Am Acad Dermatol, 2020, 82(1): 161-201.
doi: S0190-9622(19)32655-6
pmid: 31703821
|
[17] |
《脓疱型银屑病诊疗中国专家共识(2022版) 》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识(2022版)[J]. 中华皮肤科杂志, 2022, 55(3): 187-195.
|
|
Writing committee expert group on "diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement". Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement (2022)[J]. Zhonghua Pifuke Zazhi, 2022, 55(3): 187-195.
|
[18] |
Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP[J]. J Dermatol, 2018, 45(11): 1235-1270.
|
[19] |
Miao C, Chen Y, Wang Z, et al. Real-world data on the use of secukinumab and acitretin in pediatric generalized pustular psoriasis[J]. J Dermatol, 2023, 50(2): 258-261.
|
[20] |
王雅辰, 王召阳, 向欣, 等. 口服阿维A对106例儿童身高和骨骼发育影响的回顾性分析[J]. 中华皮肤科杂志, 2022, 55(12): 1073-1077.
|
|
Wang YC, Wang ZY, Xiang X, et al. Effect of oral acitretin on the height and bone development of children: a retrospective analysis of 106 cases[J]. Zhonghua Pifuke Zazhi, 2022, 55(12): 1073-1077.
|
[21] |
宋璞, 马翠玲, 樊平申, 等. 环孢素治疗儿童泛发性脓疱性银屑病临床疗效的回顾性分析[J]. 临床皮肤科杂志, 2022, 51(6): 369-372.
|
|
Song P, Ma CL, Fan PS, et al. Clinical experience with systemic cyclosporine A treatment for childhood generalized pustular psoriasis[J]. Linchuang Pifuke Zazhi, 2022, 51(6): 369-372.
|
[22] |
张娜, 李税琪, 李红文. 环孢素A治疗儿童泛发性脓疱型银屑病的临床效果[J]. 河南医学研究, 2020, 29(15): 2727-2729.
|
|
Zhang N, Li SQ, Li HW. Efficacy on cyclosporine A in the treatment of childhood generalized pustule psoriasis[J]. Henan Yixue Yanjiu, 2020, 29(15): 2727-2729.
|
[23] |
中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂及小分子药物治疗指南(2024版)[J]. 中华皮肤科杂志, 2024, 57(11): 976-997.
|
|
Chinese Society of Dermatology, China Dermatologist Association, Dermatology & Venereology Specialized Committee of Chinese Association of Integrative Medicine. Guidelines for the treatment of psoriasis with biologics and small-molecule drugs in China (2024)[J]. Zhonghua Pifuke Zazhi, 2024, 57(11): 976-997.
|
[24] |
Du Y, Yan Q, Chen M, et al. Efficacy of adalimumab in pediatric generalized pustular psoriasis: case series and literature review[J]. J Dermatolog Treat, 2022, 33(6): 2862-2868.
|
[25] |
Arasiewicz H, Lesiak A, Dec M, et al. Successful treatment of a child's generalized pustular psoriasis with adalimumab in combination with low-dose acitretin[J]. Postepy Dermatol Alergol, 2023, 40(3): 464-466.
|
[26] |
廉佳, 陈立新, 王莹, 等. 阿达木单抗联合阿维A治疗5例儿童泛发性脓疱型银屑病回顾性分析[J]. 中华皮肤科杂志, 2022, 55(10): 916-918.
|
|
Lian J, Chen LX, Wang Y, et al. Adalimumab combined with acitretin in the treatment of five children with generalized pustular psoriasis: a retrospective clinical observation[J]. Zhonghua Pifuke Zazhi, 2022, 55(10): 916-918.
|
[27] |
Liao K, Hou Z, Jing R, et al. Paediatric generalised pustular psoriasis with IL36RN mutation: successful treatment with adalimumab[J]. Indian J Dermatol, 2023, 68(6): 727.
|
[28] |
Saikaly SK, Mattes M. Biologics and pediatric generalized pustular psoriasis: an emerging therapeutic trend[J]. Cureus, 2016, 8(6): e652.
|
[29] |
Mazzotta A, Saraceno R, Esposito M, et al. Etanercept, childhood and long-term safety: a case of five years treatment[J]. Eur J Dermatol, 2011, 21(5): 776-777.
doi: 10.1684/ejd.2011.1432
pmid: 21697062
|
[30] |
Cuperus E, Koevoets R, van der Smagt JJ, et al. Juvenile interleukin-36 receptor antagonist deficiency (DITRA) with c.80T>C (p.Leu27Pro) mutation successfully treated with etanercept and acitretin[J]. JAAD Case Rep, 2018, 4(2): 192-195.
doi: 10.1016/j.jdcr.2017.08.019
pmid: 29892664
|
[31] |
Lu J, Li Y, Yu N, et al. Successful treatment of juvenile generalized pustular psoriasis with infliximab therapy: two case reports[J]. J Int Med Res, 2020, 48(3): 300060520912091.
|
[32] |
孙志琳, 刘子莲, 许媛媛, 等. 英夫利西单抗治疗青少年急性泛发性脓疱型银屑病1例[J]. 中华皮肤科杂志, 2023, 56(1): 69-70.
|
|
Sun ZL, Liu ZL, Xu YY, et al. A case of acute juvenile generalized pustular psoriasis successfully treated with infliximab[J]. Zhonghua Pifuke Zazhi, 2023, 56(1): 69-70.
|
[33] |
Pan J, Qiu L, Xiao T, et al. Juvenile generalized pustular psoriasis with IL36RN mutation treated with short-term infliximab[J]. Dermatol Ther, 2016, 29(3): 164-167.
|
[34] |
Wei K, Li P, He X, et al. Clinical efficacy and safety of secukinumab in the treatment of generalized pustular psoriasis in the pediatric population: a systematic review of the literature[J]. Front Med (Lausanne), 2024, 11: 1377381.
|
[35] |
余敏, 应掌红. 司库奇尤单抗治疗儿童泛发性脓疱型银屑病临床分析[J]. 皮肤性病诊疗学杂志, 2024, 31(4): 226-231.
doi: 10.3969/j.issn.1674-8468.2024.04.002
|
|
Yu M, Ying ZH. Clinical analysis of secukinumab in the treatment of childhood generalized pustular psoriasis[J]. Pifuxingbing Zhenliaoxue Zazhi, 2024, 31(4): 226-231.
|
[36] |
López-Sánchez C, Falla LM, Roé-Crespo E, et al. Excellent response to secukinumab in an infant with severe generalized pustular psoriasis[J]. J Dermatol, 2021, 48(6): 907-910.
|
[37] |
Guevara B, Aquino J, Diaz R, et al. Infantile generalized pustular psoriasis with excellent response to secukinumab: a case report[J]. Exp Dermatol, 2023, 32(8): 1296-1298.
|
[38] |
Chen Y, Wang Z, Liang Y, et al. Successful treatment of pediatric generalized pustular psoriasis (GPP) with spesolimab: 5 case reports and evaluations of circulating IL-36 levels[J]. J Inflamm Res, 2024, 17: 8199-8206.
doi: 10.2147/JIR.S485077
pmid: 39525315
|
[39] |
Pathak GN, Wang E, Dhillon J, et al. Spesolimab: a review of the first IL-36 blocker approved for generalized pustular psoriasis[J]. Ann Pharmacother, 2024, 307013968.
|